Transcenta Holding Limited ( (HK:6628) ) has shared an update.

Transcenta provided an update on measures to resolve the auditor’s disclaimer of opinion linked to its 2025 annual report, detailing progress on liquidity mitigation and balance-sheet strengthening. The company is advancing negotiations with global and regional pharmaceutical partners and investors to license or co-develop its lead asset osemitamab (TST001) and to secure financing for a planned global Phase 3 trial in Claudin18.2-positive gastric and gastroesophageal junction cancer.

It is also pursuing out-licensing and financing deals for other pipeline assets, including an amendment with Eli Lilly that returns two preclinical assets for US$4 million while preserving the blosozumab (TST002) license. In parallel, Transcenta is seeking up to US$100 million in new funding by year-end through diversified channels and has monetized its HiCB bioprocessing platform via a non-exclusive licensing deal with EirGenix Inc., receiving upfront and milestone payments and retaining future royalty potential, which collectively aim to ease liquidity pressure and reassure stakeholders.